Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026
Same author

Development of Surfactant-Modified Liposomal Lomustine to Improve Blood-Brain Barrier Transport and Therapeutic Outcomes in Glioblastoma.

ACS omega·2026
Same author

Resiquimod-loaded magnetic nanoparticles reprogram macrophages and induce oxidative cytotoxicity against triple-negative breast cancer cells.

International journal of pharmaceutics: X·2026
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jun 25, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Targeting multiple kinases in glioblastoma multiforme.

Sith Sathornsumetee1, David A Reardon

  • 1The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Department of Surgery, DUMC 3624, Durham, NC 27710, USA.

Expert Opinion on Investigational Drugs
|February 27, 2009
PubMed
Summary

Targeted therapy for glioblastoma multiforme (GBM) is evolving. New strategies focus on inhibiting multiple protein kinases to overcome treatment resistance and improve outcomes for this aggressive brain cancer.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Last Updated: Jun 25, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma multiforme (GBM) is a deadly brain cancer with limited treatment options.
  • Current therapies offer palliation, highlighting the need for novel treatment strategies.
  • Targeting molecular aberrations, particularly protein kinases, is a key focus in GBM research.

Purpose of the Study:

  • To review the current clinical status of targeted therapy in GBM.
  • To discuss emerging strategies for targeting multiple kinases in GBM treatment.
  • To explore approaches for overcoming resistance to kinase inhibitor monotherapy.

Main Methods:

  • Review of current literature on targeted therapy in GBM.
  • Analysis of mechanisms of resistance to single-targeted kinase inhibitors.
  • Discussion of combination strategies involving multi-targeted inhibitors or drug combinations.

Main Results:

  • First-generation kinase inhibitors show limited efficacy in unselected GBM populations.
  • Resistance to monotherapy is a significant challenge in GBM treatment.
  • Simultaneous inhibition of multiple kinases presents a promising therapeutic avenue.

Conclusions:

  • Targeted therapy is a critical area of development for GBM.
  • Multi-targeted kinase inhibition or combination therapies are essential to overcome resistance.
  • Further research into novel therapeutic strategies is crucial for improving GBM patient outcomes.